Endo combined with Mallinckrodt Pharmaceuticals in 2025 to better serve customers and improve outcomes for the patients we support. From this union, we established two focused, standalone companies: – Keenova Therapeutics, a branded therapeutics business – Par Health, a generics and sterile injectables business To learn more, follow Keenova and Par Health on LinkedIn and visit keenova.com and parhealth.com.